Exec Chat: Dexcom Continues To Evolve Blood Glucose Measurement Market

In an interview with Medtech Insight, Dexcom CEO Kevin Sayer discussed his views on the blood glucose measurement market, how he thinks it will change, and Dexcom’s responsibilities to patients, regulators and payors.

• Source: Alamy

DexCom’s presentations at the recent American Diabetes Association conference centered on the COACH study, which was looking at the clinical efficacy of its G5 and G6 continuous glucose monitors (CGMs).

The 519-patient study required patients to self-administer insulin based on self-monitored blood glucose levels for six months. After this, patients switched to CGMs for six months. The study’s primary outcome was a reduction in hypoglycemic events that required medical care

More from Diabetic Care

More from Device Area